These mechanistic insights have propelled monoclonal antibody based checkpoint blockade to the forefront of cancer immunotherapy, where PD-1/PD-L1 antagonists precisely intercept this co-inhibitory axis to restore immune-mediated tumor eradication. Here, PDCD1 is linked to neoplasm.